Humacyte will present new clinical data on its bioengineered vascular grafts at VEITHsymposium on Nov. 18, adding to investor focus on its regenerative medicine

Humacyte will present new clinical data on its bioengineered vascular grafts at VEITHsymposium on Nov. 18, adding to investor focus on its regenerative medicine pipeline. The update follows a 44% Q3 rise in hospitals ordering Symvess and recent Phase 3 trial data.